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The methanolic extract of Garcinia atroviridis (MeGa) reduces body weight and food
intake, and improves lipid profiles by altering the lipid metabolism: a rat model
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Abstract: Garcinia species are widely used for their slimming effects via increased fat burning and suppression of satiety. However,
scientific evidence for the biological effects of Garcinia atroviridis (GA) is lacking. We investigated the phytochemical composition,
safety profiles, and antioxidant and antiobesity effects of methanolic extracts of Garcinia atroviridis (MeGa) in obese female rats.
Repeated dose toxicity studies were conducted according to the OECD guidelines. Upon sacrifice, haematological, biochemical, lipid
profile, and serum-based metabolomics analyses were performed to evaluate metabolic expression changes and their related pathways.
MeGa contains several phytochemical groups and GA fruit acids. MeGa was found to be nontoxic in both male and female rats with
an oral lethal dose (LD50) of 2000 mg/kg. After 9 weeks of treatment, MeGa-treated obese rats had lower weight gain and better
lipid profiles (cholesterol and triglyceride), which correlated with the altered metabolic pathways involved in the metabolism of lipid
(glycerophospholipid) and biosynthesis of unsaturated fatty acid. In addition, MeGa caused differential metabolism pathways of
arachidonic acid and tryptophan that affect the inflammatory response and suppression of appetite. We concluded that MeGa is safe,
and its slimming effects are due to the differential metabolism of lipids.
Key words: Obesity, Garcinia atroviridis, phytochemistry, toxicity, antiobesity, metabolomics

1. Introduction
More than 650 million people were obese in 2016, as
reported by the World Health Organization (WHO)1;
the numbers were increasing at an alarming rate in 2018.
Health professionals such as doctors, pharmacists, and
nurses have important roles in advising patients and the
general public on weight management strategies, which
include appropriate diet with the correct nutrients. Diet
is, therefore, the indispensable factor that influences the
ability to lose weight or maintain body weight (Keränen
et al., 2009; Soeliman and Azadbakht, 2014). Therefore,
evidence-based knowledge on local fruits with beneficial
effects on weight management may provide practitioners
with safer alternatives for developing weight management
strategies in their patients as well as the general public.
1
World Health Organization (2020). Fact Sheet. Obesity and
overweight [online]. Website https://www.who.int/en/newsroom/fact-sheets/detail/obesity-and-overweight [accessed 2
April 2020].

‘AsamGelugor’ or ‘Asamkeping’ is the popular name for
Garcinia atroviridis (GA)Griff. ex T. Anders in Malaysia
(Alsarhan et al., 2014). It is widely distributed in Peninsular
Malaysia, Thailand, Myanmar, and India (Mackeen et al.,
2000; Hamidon et al., 2017). Almost all parts of the tree
such as fruit, leaves, roots, and stem bark can be used
either for food seasoning or medicinal purposes, including
antioxidant, antiobesity, antiinflammatory, and cytotoxic
activities (Pangsuban et al., 2009; Hamidon et al, 2017). GA
leaf extract possesses antioxidant properties with protondonating ability serving as a free-radical scavenging agent
(Nursakinah et al., 2012). The presence of hydroxycitric
acid (HCA) in GA has been documented to have potent
antioxidant potential (Rittirut and Siripatana, 2006). HCA
originated from Garcinia species has been widely used
around the world as a food supplement for its claimed
benefit in weight management for decades. HCA is able
to control body weight and appetite by blocking the
lipogenesis process (a process that converts carbohydrates
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to fat) through the inhibition of ATP-citratelyase
production in cells (Chuah et al., 2012; Hamidon et al.,
2017). Furthermore, HCA is believed to improve the level
of blood cholesterol and dilation of blood vessels, and
reduces excessive fat absorption (Yapwattanaphun et al.,
2002).
Overweight and obesity are measured with body
mass index (BMI) and are characterized by an abnormal
or excessive deposition of fat tissues when energy intake
and expenditure are imbalanced, attributed mainly to
poor dietary choices (imbalanced and high fat diet) and
physical inactivity (sedentary behaviour) (WHO, 2020).
It exerts profound perturbation on the metabolism,
mainly in lipid metabolism and glucose metabolism,
which may lead to hyperlipidemia, hypertension, and
diabetes (WHO, 2020). Obesity-associated metabolic
changes can be tracked through altered metabolites (small
molecules) in a cell, tissue, or organism. For example,
altered metabolites associated with obesity phenotypes
have been identified and are linked to BMI changes in
humans (Abu Bakar et al., 2015; Park et al., 2015; Cirulli
et al., 2019). The metabolic phenotypes can be interpreted
biochemically and biologically using these identified
metabolites through metabolomics study (identifying all
metabolites in a biological sample). It is useful to identify
the biomarkers and metabolic pathways associated with
obesity in designing and developing better therapeutic
targets. Therefore, the metabolomics approach was used to
identify the obesity-affected mechanisms underlying the
antiobesity activity of MeGa extract in a rat model.
Although herbs are derived from the nature, their safety
is not guaranteed, and some may have unexpected adverse
effects, including acute liver injury and fatal herb–drug
interaction (Crescioliet al., 2018; Kothadia et al., 2018).
Many herbal products lack scientific evidence on their
safety profiles and their respective mechanisms of actions
before they are marketed. Despite many studies reporting
on the antioxidant and weight reduction properties of the
leaves and fruit extracts of GA (Alias et al., 2017; Hamidon
et al., 2017; Lumbantobing et al., 2017), no comprehensive
study is available on the safety of GA extracts according
to standard guidelines such as good laboratory practice
and OECD. Therefore, phytochemical composition and
safety limits of the methanolic extract of GA (MeGa) fruit
were investigated and a metabolomics study was further
conducted to study the changes of metabolic pathways in
obese rats treated with MeGa.
2. Materials and methods
2.1. Chemicals and reagents
Methanol (Merck, Darmstadt, Germany), formalin,
and diethyl ether of analytical grade were obtained
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from Fisher Scientific (Bridgewater, NJ, USA). Other
chemicals used in this study include magnesium,
hydrochloric acid, concentrated sulphuric acid, 10% ferric
chloride, chloroform, stable free radical 2,2-diphenyl-1picrylhydrazyl (DPPH), Trolox, Folin–Ciocalteu reagent,
sodium carbonate, gallic acid, ethanol solution, and 2%
(w/v) aluminium chloride.
2.2. Analysis of the methanolic extract of Garcinia
atroviridis (MeGa)
2.2.1. Preparation of the MeGA
Garcinia atroviridis (GA) fruits were collected from a
local village in Seremban, Malaysia. The plant specimen
was sent for species identification to the Forest Research
Institute Malaysia (FRIM); a certificate with sample no.
PID 110214-07 was obtained. Ripe fruits were plucked and
chopped into small pieces and dried using a FreeZone Plus
12 Liter Cascade Freeze Dryer (Labconco, Kansas City,
MO, USA) before being ground by mechanical grinder
(SY-04, Himitzu, Japan). The powdered samples were
stored in an air-tight bottle. The powdered samples (100
g) were soaked in methanol (ratio of powder to solvent:
1:20) for 3 days before filtering using Whatman No 1 filter
paper (Whatman™, Dassel, Germany). The filtrate was
concentrated using a Rotavapor® R-210 Rotary Evaporator
System (Buchi, Flawil, Switzerland) at a setting of not
more than 50 °C. Pure methanolic extract of GA (MeGa)
was stored at 4 °C until further analysis. The yield of the
extract was calculated as percentage yield (%) = {[Weight
of dry crude extract (g)/weight of plant material before
extraction (g)] ×100%}.
2.2.2. Phytochemical analysis and assessment of
antioxidant assay
Various phytochemical groups (flavonoid, phenol, tannin,
saponin, steroid, phlobatanin, and terpenoid) were
identified using methods described by Harborne (1998)
and Kokate (2005). Total flavonoid content (TFC) and
total phenolic content (TPC) of MeGa were quantitated
spectrophotometrically with the aluminium calorimetric
method (quercetin as the reference standard) and Folin–
Ciocalteu method (gallic acid as the reference standard),
respectively. The antioxidant capacity of MeGa was
assessed using 2,2-diphenyl-1-picrylhydrazyl (DPPH) free
radical-scavenging assay (Trolox as the reference standard)
with slight modifications (Yang et al., 2011). All of the
experiments were conducted in triplicate following the
protocol previously reported by Abdul Hisam et al. (2018).
2.2.3. Metabolite profiling of the MeGa
Liquid chromatography mass spectrometry/quadrupole
time of flight (LC/MSQ-TOF) was used to profile
compounds in MeGa. The stock solution (1 mg/mL) was
first purified using the solid phase extraction method
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(Bond Elut C18, Agilent Technologies, Santa Clara, CA,
USA) before being analysed by LC/MSQ-TOF (model
6520 Agilent Technologies). A ZORBAX Eclipse Plus
C18 column set (100 mm × 2.1 mm × 1.8 µm; Agilent
Technologies) at 40 °C was used. The mobile phases
consisted of water with 0.1% formic acid (A) and
acetonitrile with 0.1% formic acid (B). The flow rate was
set at 0.25 mL/min with 5% of mobile phase Band 95% of
mobile phase A over a linear gradient of 36 min. The total
run time was 48 min per sample analysis. The electrospray
ionization (ESI) source (capillary voltage 4000 V, skimmer
65 V, and fragmentor 125 V), the nebulizer (45 psi), the
nitrogen drying gas (flow rate at12 L/min, 350 °C) were
set up properly. Data acquisition was collected from a full
scan over 100 to 1000 m/z in positive ESI mode. During
the analysis, both reference masses of C5H4N4 (121.0509
m/z) and C18H18O6N3P3F24 (922.0098 m/z) were injected
continuously to deliver accurate mass signals.
2.3. Animal experiments and dietary treatments
Sprague-Dawley rats were donated by the Laboratory
Animal Facility and Management (LAFAM), Faculty of
Pharmacy, Universiti Teknologi MARA (UiTM). Rats
were randomly assigned according to the study protocol.
Rats (180–220 g) were given 7 days to acclimate to the
new laboratory conditions prior to dosing. The rats
were individually housed in a ventilated caging system
and exposed to a regular 12-h light–dark cycle at room
temperature set at 27 ± 2 °C. The rats were allowed to
access the food and water ad libitum. Dietary descriptions
are detailed in Table A1. Briefly, the rats were fed with
normal fat diet (NFD) (D12450B, Research Diets Inc.,
New Brunswick, NJ, USA) for the control/lean group and
high fat diet (HFD) (D12492, Research Diets Inc.) for the
obese group. Rats were euthanized by cervical dislocation
at the defined time after collecting blood samples as
necessary. The research proposal was approved by the local
research ethics committee on animal study (UiTM Care,
Ref: 69/2015).
2.4. Rat model for toxicity study
2.4.1. Acute toxicity effect of the MeGa
An acute toxicity study was performed according to the
stepdown procedure in accordance with the OECD 423
guidelines. This is a short-term toxicity study to determine
the dosage of MeGa for a subsequent subacute toxicity
study. For control (n=3 female rats) and test (n=3 female
rats) groups, Sprague-Dawley rats were orally administered
distilled water and 2000 mg/kg of MeGa, respectively.
Clinical signs of toxicity in the rats were observed for the
first 30 min, then 4 h, and daily thereafter up to 14 days.
The mortality rate was recorded.

2.4.2. Subacute toxicity effect of the MeGa
According to the OECD 407 guideline, the subacute
toxicity study of MeGa extract was conducted using a
repeated dose over 28 days. Body weights of 4-weekold Sprague-Dawley rats were recorded and randomly
assigned to control, test, and satellite groups (10 rats/
group) according to sex. The limiting dose (1000 mg/kg)
was prepared in distilled water and orally administered
as a single daily dose to the test group and satellite group,
while the control group received only distilled water orally.
Toxic manifestations and mortality were monitored daily.
Body weights, food intake, and water intake of all of the
rats were recorded daily. The rats were euthanized after
28 days of treatment except for the satellite group, the
rats of which were observed for another 14 days without
treatment.
2.4.3. Haematological and biochemical analysis
Blood samples were withdrawn via cardiac puncture for
the haematological and biochemical analyses using EDTAanticoagulated whole blood and serum from clotted blood,
respectively. Haematological analysis was performed
using a fully automated haematological analyzer (Advia
2120i Siemens, Washington, DC, USA) at the Centre of
Pathology Diagnostic and Research Laboratory (CPDRL),
Universiti Teknologi MARA, Sungai Buloh. Biochemical
analysis was performed at the Veterinary Laboratory
Service Unit (VLSU), Universiti Putra Malaysia (UPM).
2.4.4. Relative organ weight
Rats were euthanized by cervical dislocation on the 29th
day. Brains, hearts, lungs, livers, kidneys, and spleens were
excised, weighed, and examined for any macroscopic
changes. The relative organ weights were calculated as
relative organ weight (%) = {[Absolute organ weight (g)/
body weight of rats on sacrifice day (g)] × 100%}.
2.4.5. Histopathological examination
For histopathological examination, vital organs such
as kidneys and livers were preserved in 10% formalin
before sectioning. Thin tissue sections were stained with
haematoxylin–eosin (H&E) stain and examined for any
morphological changes and abnormalities under a light
microscope at VLSU, UPM.
2.5. Rat model for antiobesity study
Female 4-week-old Sprague-Dawley rats were induced to
be obese using a high-fat diet (HFD). After 6 months of
feeding, the rats achieved an average of more than 10%
increase in weight compared to the lean group; they were
classified as moderately obese according to a previous
definition (Thibault, 2013).
2.5.1. Antiobesity effect of the MeGa
The rats were randomly grouped (n=6 rats/group) to
receive treatment as follows: (i) lean rats without treatment
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(negative control); (ii) moderately obese rats without
treatment (positive control); (iii) moderately obese rats
treated with 15 mg/kg of Adipex (positive control with
treatment); (iv) moderately obese rats treated with 100
mg/kg of MeGa (Ga-1); (v) moderately obese rats treated
with 200 mg/kg of MeGa (Ga-2); (vi) moderately obese
rats treated with 400 mg/kg of MeGa (Ga-3). Body weights
of the rats were recorded weekly.
2.5.2. Biochemical analysis of antiobesity rat model
Blood samples were withdrawn from the orbital sinus of
the rats at 2 different time points, i.e. pretreatment and
posttreatment. Serum was then used for the measurement
of lipid profiles.
2.5.3. Metabolite profiling of antiobesity rat model
A total of 200 µL of serum was diluted with 150 µL of dH20
(pH10); 300 µL of cold acetonitrile was added, followed
by vortex mixing for 1 min for protein precipitation.
The samples were centrifuged for 10 min at a speed of
10,621 g (Eppendorf Centrifuge 5804R; Eppendorf North
America, Framingham, MA, USA), and the supernatant
was subjected to protein precipitation another 2 times.
The total supernatant collected was spin-dried using a
centrifugal concentrator (Eppendorf Concentrator Plus).
Dried sample was then reconstituted with 40 µL of mobile
phase (water:acetonitrile, 95:5) followed by a brief vortex
mixing of 1 min, and then spun at 10,621 g for 10 min.
Thirty (30) µL of the supernatant was transferred into
an autoinjector vial and injected into the LC/MSQ-TOF
system for analysis.
2.5.4. Compound identification
The LC/MS QTOF output was analysed using Mass Profiler
Professional Version B.12.01 (Agilent Technologies), which
provided multivariate statistical analysis for comparative
metabolite profiles. Principal component analysis (PCA)
was used to examine the clusters and outliers from the
input data sets without prior information on sample
grouping. A3-dimensional data set of the aligned features
detected in all of the biological replicates was generated
for visualisation. One-way analysis of variance (ANOVA)
determined changes in the metabolites across groups after
Benjamin Horchberg correction. Identified metabolites
were annotated by mass analysis using the METLIN
database2 and Kyoto Encyclopedia of Genes and Genomes
(KEGG) database3 before pathway analysis was performed
using Metaboanalyst4.
2.6. Statistical analyses
Statistical analyses for haematological and biochemical
parameters were carried out using the SPSS, version 20.
https://metlin.scripps.edu/landing_page.
php?pgcontent=mainPage
2

http://www.genome.jp/kegg/

3

https://www.metaboanalyst.ca/

4
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The data were expressed as the mean ± standard error of
the mean (SEM) values. An independent t-test was used
to compare the mean of 2 groups. To compare among
groups, one-way analysis of variance (ANOVA) was used
followed by a post hoc test, Tukey LSD, to identify the
paired data that differed significantly. To compare pre- and
posttreatment, the paired sample t-test was used. Data was
considered statistically significant when P-value was less
than 0.05.
3. Results
3.1. Phytochemical analysis, antioxidant activity, and
metabolite profiling of the MeGa extract
The yield of the methanolic extract of Garcinia atroviridis
(MeGa) was approximately 9%–10% after complete
drying. Phytochemical screening of MeGa revealed the
presence of flavonoid, phenol, saponin, and terpenoids;
tannin, steroid,and phlobatanin were not detected. The
total phenolic and flavonoid contents of MeGa were 8.833
± 1.18 μg/mg gallic and 0.821 ± 0.08 μg/mg quercetin,
respectively. For DPPH antioxidant ability, the IC50 of
MeGa (173.33 ± 13.33 μg/mg) was higher than Trolox
(IC50 of 54.67 ± 2.67 μg/mg), suggesting that MeGa
has a statistically lower radical scavenging ability than
Trolox. The chromatographic profiles of the extracts
were obtained from different batches of MeGa extracts.
There are 5 metabolites that were consistently present
in all the batches of MeGa extracts: hydroxycitric acid,
2-(butoxycarbonylmethyl)-3-butoxycarbonyl-2-hydroxy3-propanolide, tartaric acid, malic acid, and ascorbic acid
(Table A2).
3.2. Toxicity studies
3.2.1. Acute toxicity study of the MeGa
No visible toxicity sign was observed in the rats treated
with 2000 mg/kg of MeGa. Neither behavioural changes
nor mortality were observed in the rats over 14 days. The
LD50 (lethal dose, 50%) of the MeGa was higher than
2000 mg/kg, as no lethal effect was recorded. According
to the Globally Harmonized System of Classification and
Labelling of Chemicals (GSH), MeGa is classified under
Category 5, as it is considered safe with low toxicity effect.
Therefore, 100 mg/kg, 200 mg/kg, and 400 mg/kg oral
doses of MeGa were applied in the subsequent subacute
toxicity study.
3.2.2. Subacute toxicity study of the MeGa
There were no observable behavioural changes in the
MeGa-treated group versus the untreated group. Body
weight, food intake, haematological indices, biochemical
parameters, and relative organ weights (Table A3) were
compared between the MeGa-treated and untreated rats.
There were no deaths recorded in the rats of either sex
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from the treatment groups or the control group. MeGatreated and control rats appeared to be healthy throughout
the 28 days of the treatment period. Subacute toxicity
results were comparable to the earlier acute toxicity study
on MeGa.
3.2.3. No histopathological changes in liver and kidney
tissues
Histopathological analysis was performed on the liver and
kidney samples to examine for structural abnormalities
on the hepatocytes (liver cells) and kidney cells after
treatment with MeGa. The liver samples showed normal
architecture with well-defined cytoplasm, cell lining, and
round nuclei in hepatic cells (Figures 1a–1d). Histological
study of the kidneys for both control and treated groups
displayed normal glomeruli networks of small blood
vessels surrounded by the Bowman’s capsule and proximal
and distal convoluted tubules, without any sign of
inflammation (Figures 1e–1h).
3.3. Antiobesity study
The rats in whom obesity was induced for 6 weeks using
a high-fat diet (HFD) had body weights which were
statistically different from rats in the lean group (Figure
A1). These obese rats were then treated with MeGa or
Adipex.
3.3.1. Reduction in body weight and food intake in
MeGa-treated rats
Obese rats treated with MeGa showed lower body weights
than untreated obese rats. The most effective dose for
weight reduction was seen in the Ga-2 group (200 mg/kg
MeGa), whereby their body weights showed no significant
differences from those of the lean group (Figure 2a). After
4 weeks of treatment, the amount of food consumed by
the rats treated with Adipex and the Ga-2 group was
reduced compared to the obese and lean rats. Lean and
obese groups showed similar food intake patterns, while
both Adipex and Ga-2 groups had reduced food intakes.
These changes were noticeable after 3 weeks of treatment
(Figure 2b).
3.3.2. Improved lipid profiles in MeGa-treated rats
The obese group fed with a high fat diet (HFD) was found
to have increased levels of total cholesterol, triglycerides,
and LDL (P-value < 0.05), and a decreased level of HDL
compared to the lean rats. In the Adipex group, the
cholesterol level measured posttreatment was statistically
significantly reduced compared to the pretreatment
cholesterol level. The posttreatment HDL level was slightly
reduced compared to pretreatment, while triglyceride and
LDL levels were slightly increased (without a statistical
difference) in the Adipex-treated rats. In the Ga-2 group,
both cholesterol and triglyceride levels were significantly
decreased in the posttreatment rats. For HDL and LDL,

the posttreatment levels were decreased in the Ga-2–
treated rats (Figure 3).
3.3.3. Metabolite profiling of MeGa-treated rats
The chromatograms for samples obtained from the
lean, obese, Adipex-treated, and MeGa-treated rats
demonstrated different metabolite profiles (Figure A2).
Principal component analysis (PCA) illustrated distinct
separation of the metabolite profiles between the lean rats
and obese rats as well as pretreatment and posttreatment
(Figure 4a). Metabolic pathways that were discovered
to be associated with obesity and in response to MeGa
included the alpha-linolenic acid metabolism (impact:
1), sphingolipid metabolism (impact: 0.27821), steroid
hormone biosynthesis (impact: 0.23648), tryptophan
metabolism (impact: 0.13284), steroid biosynthesis
(impact: 0.12448), retinol metabolism (impact: 0.12371),
tyrosine metabolism (impact: 0.05788), and the
biosynthesis of unsaturated fatty acids (impact: 0) (Figure
4b). The differentially regulated metabolites are shown in
Table A4.
4. Discussion
As reported in the literature, the methanolic extract of
Garcinia atroviridis (MeGa) containsflavonoid, phenol,
saponin, and terpenoid (Nursakinah et al., 2012). A
previous study had shown that the concentration of
phenolic compounds is correlated with the antioxidant
capacity of an extract (Chatha, 2014). Antioxidant
capacity is one of the commonly determined parameters
for bioactive components with pharmacological activities.
MeGawas tested using DPPH assay for free-radical
scavenging ability; its antioxidant activity was significantly
lower than that of Trolox. The antioxidant activity
exhibited by MeGa indicates its potential to neutralise free
radical compounds. Garcinia atroviridis (GA) has been
reported to have ow antioxidant activity as determined
by DPPH assay (Abdullah et al., 2013). The availability
and stability of phenolic and flavonoid may contribute
to this antioxidant activity. Among the GA fruit acids,
hydroxycitric acid (HCA), citric acid, tartaric acid, and
ascorbic acid contribute to the antioxidant activity of GA
(Rittirut and Siripatana, 2006; Hamidon et al., 2017). HCA
was detected as one of the main compounds in MeGa. As
reported previously, HCA is believed to induce weight
loss via reducing the lipogenesis process and through the
suppression of appetite (Chuah et al., 2012).
In this study, rats treated with MeGa had a reduced
rate for the increment of body weight and no significant
difference in the body weight increment when compared
to the lean group. This could be due to the inhibition of
fatty acid synthesis by HCA in MeGa. In the liver, HCA
acts as a potent competitive reversible inhibitor of ATP-
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(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 1. Histopathological examination of liver and kidney cells in the Sprague-Dawley rats for the control
and MeGa treated groups. Liver cells of the (a) control rat with H&E stain ×10 magnification, (b) control
rat with H&E stain ×40 magnification, (c) treated rat with H&E stain ×10 magnification, (d) treated rat
with H&E stain ×40 magnification. Kidney cells of the (e) control rat with H&E stain ×10 magnification, (f)
control rat with H&E stain ×40 magnification, (g) treated rat with H&E stain ×10 magnification, (h) treated
rat with H&E stain ×40 magnification. Abbreviation: CV = convoluted tubule.

citrate lyase and an inhibitor that disrupts fatty acid
synthesis (Chuah et al., 2013). An earlier study reported
that HCA caused reduction of food intake and body weight
gain in rats given high sucrose, high glucose, and high
sucrose with fat (Leonhardt et al., 2001). HCA was found
to inhibit the function of ATP-citrate lyase by preventing
the conversion of citrate into oxaloacetate and acetyl-
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CoA (Amran et al., 2009). Limited acetyl-CoA perturbs
the biosynthesis of fatty acid and cholesterol. Inhibition
of acetyl-CoA production directly depletes the amount
of subsequent metabolites (called malonyl-CoA) in the
fatty acid synthetic pathway. Malonyl inhibits the enzyme
carnitine acyltransferase from oxidizing fat. Indirectly, it
is proposed that HCA reduces the formation of malonyl-
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Figure 2. Antiobesity assessment of the MeGa extract in different treatment groups. The changes of (a)
body weight (b) food intake in lean (normal control group fed with normal fat diet (NFD) (also called
chow diet) that contains 10% fat, obese (experiment group fed with high-fat diet containing 60% fat),
Adipex (experiment group fed with high-fat diet and treated with Adipex drug) and Ga [experiment
groups fed with MeGa, i.e. 100 mg/kg (Ga-1), 200 mg/kg (Ga-2) and 400 mg/kg (Ga-3)], * indicates
significant difference compared with lean group, P-value < 0.05), # indicates significant difference
compared to the Ga-2 group, P-value < 0.05) using ANOVA post hoc, Tukey LSD. Body weight gains
around 10%–25% compared to lean control were considered moderate obesity.

CoA and therefore stimulates fat metabolism. Due to these
metabolic alterations, a signal is then delivered to the
brain to increase the serotonin level with a concomitant
reduction in appetite. In human trials, HCA has been
reported to cause a profound reduction in appetite and

weight loss concomitant with an improved lipid profile
(Chuah et al., 2013).
In this study, treatments with MeGa and Adipex
reduced the levels of total cholesterol, triglyceride, and
LDL in the obese rats. This suggests that MeGa possesses
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Figure 3. Lipid profile of rats in lean, obese, Adipex- and Ga-2 treated groups. (a)
Cholesterol level, (b) triglyceride level, (c) high-density lipoprotein (HDL) level and (d)
low-density lipoprotein (LDL) level. * indicates significantly different pretreatment group,
P-value < 0.05 using paired sample t-test.

antiobesity activity with an improvement of lipid profiles,
as displayed by the obese rats. As previously mentioned,
HCA is a competitive inhibitor of ATP-citrate lyase, which
controls the availability of acetyl-CoA for the synthesis of
cholesterol and triglyceride. HCA has also been found to
reduce cholesterol levels through a series of processes, such
as interruption of intestinal cholesterol uptake, conversion
of cholesterol into bile acids, and excretion of intestinal
bile acids. HCA decreases the levels of cholesterol and
triglyceride by inhibiting the endogenous synthesis of
cholesterol and triglyceride via inhibition of the synthesis
of acetyl-CoA.
The score plot from principal component analysis
(PCA) illustrated an obvious separation between the lean
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rats and other groups of rats before and after treatment
regimes. Metabolic pathway analysis (MetPA) revealed 22
affected metabolic pathways which differentiated MeGatreated obese rats from lean rats. These pathways include
the biosynthesis of unsaturated fatty acids and steroid,
metabolism of tyrosine, retinol, tryptophan, sphingolipid,
and alpha-linolenic acid. Comparing the metabolome
of these 4 studied groups (lean, obese, Adipex-treated,
Ga-2-treated), most of the identified metabolites and
metabolism pathways were linked to the control of
energy balance and the role of mitochondria. Metabolites
linked with these metabolism pathways are acylcarnitine,
phosphatidylcholine, L-kyeunerine, and arachidonic
acid. Acylcarnitine is the main transporter involved in
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Figure 4. Metabolite profiling of rats in lean, obese, Adipex- and Ga-2 treated groups. (a) PCA score plot of
metabolite profiles of rats in different treatment using Mass Profiler Professional software. (b) Metabolic pathway
analysis using Metabolomics Pathway Analysis (MetPA) software.

the energy production process. It carries activated longchain fatty acids (the breakdown products of fatty acids
and amino acids) into mitochondria for the β-oxidation
process (Tarasenko et al., 2018). Acylcarnitine also serves
as an important biomarker of mitochondrial dysfunction
with an increase of acylcarnitines (Chen et al., 2015).

Lipid is an important source of energy reserves.
Elevated lipid profiles (increase fatty acids or cholesterol)
in the bloodstream are associated with an increased risk
for cardiovascular-related diseases, including coronary
heart disease (excessive fat deposition in blood vessels),
diabetes (high blood sugar), and hypertension (high
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blood pressure). In the hepatic and muscle mitochondria,
free fatty acids (FFAs) are broken down to generate
energy through catabolic processes such as the fatty acid
β-oxidation and tricarboxylic acid cycle (TCA cycle).
Excess lipids are stored in fat tissues (adipose tissue)
and accumulated elsewhere in the form of triglycerides.
Obesity is characterized by increased lipid deposition
and decreased lipid removal in tissues, as well as with
an elevated level of FFAs in plasma. In line with this,
the alteration of serum FFA levels in obese animals was
investigated using metabolomics analysis to decipher
the affected pathways. Furthermore, saturated fatty acids
(SFAs) in the composition of serum FFAs have been linked
to the development of obesity.
In the metabolomics analysis, the highest impact score
is that of the biosynthesis of fatty acids. Malonyl-CoA not
only serves as an essential substrate for the biosynthesis
of fatty acids, but also limits the supply of fatty acid into
mitochondria. In other words, the availability of fatty
acids in mitochondria stimulates the lipogenesis process
and directly accelerates oxidation of glucose in response
to acetyl-CoA carboxylase, which is activated by insulin.
A previous study had reported that obese individuals
have higher malonyl-CoA levels but lower rates of fatty
acid oxidation compared to healthy individuals (Chen et
al., 2015). Apart from malonyl-CoA, other compounds
detected were acetyl carnitine and phosphatidylcholine.
Acetyl carnitine is involved in the metabolism of fatty
acids; it is one of the important metabolites associated
with obesity. Fatty acids undergo oxidation actively with
the provision of FFAs in the body. In the presence of
acetyl carnitine, fatty acids undergo esterification and are
transferred to mitochondria for subsequent β-oxidation
to produce energy. Phosphatidylcholine is the major
phospholipid component found in all plasma lipoprotein.
In the liver, biosynthesis of phosphatidylcholine is
important for the secretion of plasma lipoproteins
such as very low density lipoprotein (VLDL) and high
density lipoprotein (HDL). In the cell membranes,
lipolytic enzymes (e.g., phospholipase D) metabolize
phosphatidylcholine into several isoforms of lipids (e.g.,
phosphatidic acid and choline). Hepatic and serum
phosphatidylcholine levels were higher in obese mice than
in normal mice (Kim et al., 2011). Choline, an essential
dietary nutrient, not only protects the integrity of cellular
structure, but also regulates one-carbon metabolism
(methyl, CH3) and transportation of lipid/cholesterol.
In animals, the synthesis of phosphatidylcholine via the
Kennedy pathway requires a high percentage of choline
(more than 95%) in the tissues (Xie et al., 2012). For the
synthesis of methionine from homocysteine, choline
oxidizes to betaine in the mitochondria of the liver and
kidney to supply the methyl groups.
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Apart from that, the branched chain amino
acids (BCAAs), which are nutritionally essential
for the metabolism of amino acids, were detected
in this study. They are N-acetylserotonin, 4,
6-dihydroxyquinoline, L-kynurenine, L-normetanephrine,
4-hydroxyphenylacetaldehyde,
4-fumarylacetoacetate,
and
S-methyl-5-thio-D-ribose
1-phosphate.
The
BCAAs are important in regulating synthesis of protein,
metabolism of glucose, and oxidation, as well as secretion
of leptin from fat (Xie et al., 2012). These BCAAs as well as
aromatic amino acids might be used to promote synthesis
of protein by changing the metabolic direction of amino
acids, as indicated in HCA-treated male rats (Han et al.,
2016a). Therefore, it is postulated that obesity may perturb
the catabolism pathways of BCAA.
HCA is structurally similar to citrate, which plays an
important role in allosteric regulation for a number of
enzymes involved in the metabolism of carbohydrates
and fats (Han et al., 2016a). The metabolomics approach
adopted by our study further supported that the pathways
involved in the metabolism of lipid (glycerophospholipid)
and biosynthesis of unsaturated fatty acid were perturbed
in rats treated with MeGa. Similar to another study by Liu
et al. (2015), we also observed changes in the lipid profiles
of the rats treated with MeGa. The mechanisms associated
with such findings are explained by the inhibition of ATPcitrate lyase (ACLY) activity. In addition, Liu et al. (2015)
further explained that the reduced fat accumulation in the
liver of HFD rats treated with Garcinia cambogia mainly
occurred due to the lipolysis of exogenous triglyceride, as
observed with the increase of the mRNA levels of adipose
triglyceride lipase. In addition, the adiponectin–AMPK
signalling pathway was also stimulated with increased
mRNA levels of adenosine 5’-monophosphate-activated
protein kinase (AMPK) α1 and adiponectin receptor 1.
However, there was no suppression of the synthesis of
endogenous triglyceride, as no change to the mRNA levels
of ACLY, fatty acid synthase (FAS), or Acyl-CoA oxidase
genes were found (Liu et al., 2015). However, (-)-HCAtreated broiler chicken and primary culture of chicken
hepatocytes have been reported to show changes in the
hepatic mRNA expressions involved in the metabolism of
lipids. Expression of genes related to the synthesis of fatty
acids such as FAS, sterol regulatory element binding protein1c (SREBP-1c)], and ACLY genes were downregulated,
while the peroxisome proliferators-activated receptor α
(PPARα) gene was upregulated (Han et al., 2016b; Li et al.,
2017). Further metabolomics investigation indicated that
(-)-HCA was involved in the metabolisms of amino acids,
protein synthesis, citric acid cycle, and synthesis of uric
acid and fatty acids in controlling weight gain and lipid
accumulation (Peng et al., 2017). Our findings thus far
support that MeGA reduced body weight and maintained
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desirable lipid profiles via its control over the metabolism
of lipids which might be regulated by the differential
expression of genes, such as FAS, SREBP-1c, ACLY, and
PPARα. However, further investigations into their precise
mechanisms are required.
Current research findings have demonstrated that
MeGa successfully reduced body weight gain and
maintained desirable lipid profiles in the obese rats. It
is a good weight management alternative and safe for
consumption according to the safety information obtained
from the OECD guidelines. There are two (2) main benefits
observed in rats treated with MeGa: (i) reduced weight
gain by reduction in the amount of food intake (suppressed
food intake), and (ii) improved lipid profiles in the
alteration of the biosynthesis of fatty acids and metabolism

of lipids. Therefore, MeGA is a safer alternative that can be
consumed as part of a weight management programme.
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Table A1. Ingredient compositions of experimental diets according to the acute, subacute toxicity and antiobesity studies. Abbreviation:
Ctrl = control; Sat. = satellite.

Class

Protein

Carbohydrate

Fiber
Fat
Mineral
Vitamin

Dye

Caloric
information

Oral
administration

Acute toxicity
study

Subacute toxicity study

Antiobesity study

Ctrl

Test

Ctrl

Test

Sat.

Lean

Obese

NFD

NFD

NFD

NFD

NFD

NFD

Casein, Lactic, 30 Mesh

189.56

189.56 189.56

L-Cystine

2.84

2.84

Ingredients / Caloric
information

2.84

HFD

Adipextreated
obese
HFD

MeGatreated
obese
HFD

189.56 189.56 189.56

258.45

258.45

258.45

2.84

3.88

3.88

3.88

2.84

2.84

Sucrose, Fine granulated 335.53

335.53 335.53

335.53 335.53 335.53

94.08

94.08

94.08

Corn starch

298.56

298.56 298.56

298.56 298.56 298.56

-

-

-

Lodex 10

33.17

33.17

33.17

33.17

33.17

33.17

161.53

161.53

161.53

Solka Floc, FCC200

47.39

47.39

47.39

47.39

47.39

47.39

64.61

64.61

64.61

Soybean oil

23.70

23.70

23.70

23.70

23.70

23.70

32.31

32.31

32.31

Lard

18.96

18.96

18.96

18.96

18.96

18.96

316.60

316.60

316.60

Mineral mix

47.39

47.39

47.39

47.39

47.39

47.39

64.61

64.61

64.61

Choline Bitartrate

1.90

1.90

1.90

1.90

1.90

1.90

2.58

2.58

2.58

Vitamin mix

0.95

0.95

0.95

0.95

0.95

0.95

1.29

1.29

1.29

Yellow dye (FD&C #5)

0.05

0.05

0.05

0.05

0.05

0.05

-

-

-

Blue dye (FD&C #1)

-

-

-

-

-

-

0.06

0.06

0.06

Total (g)

1000

1000

1000

1000

1000

1000

1000

1000

1000

Protein (% Kcal)

20

20

20

20

20

20

20

20

20

Fat (% Kcal)

10

10

10

10

10

10

60

60

60

Carbohydrate (% Kcal)

70

70

70

70

70

70

20

20

20

Energy density (Kcal/g)

3.82

3.82

3.82

3.82

3.82

3.82

5.21

5.21

5.21
100 mg/kg
(Ga-1),
2000
1000 1000
Distilled
Distilled
Distilled Distilled 15 mg/kg 200 mg/kg
mg/kg
mg/kg mg/kg
(Ga-2),
water
water
water
water
Adipex
MeGa
MeGa MeGa
400 mg/kg
(Ga-3)

Normal fat diet (NFD), also called chow diet (D12450B, Research Diets, USA); high-fat diet (HFD) (D12492, Research Diets, USA);
Methanolic extract of Garcinia atroviridis (MeGa) was used for toxicity study (acute and subacute) and antiobesity study. There are two
groups in acute toxicity study: control (chow diet) and test (chow diet) + 2000 mg/kg MeGa groups. There are three groups in subacute
toxicity study: control (chow diet), test (chow diet) + 1000 mg/kg MeGa and satellite (chow diet) + 1000 mg/kg MeGa groups. For
antiobesity study, there are four main groups: lean (NFD), obese (HFD), Adipex-treated obese (HFD + 15 mg/kg Adipex) and three
subgroups of MeGa-trated obese [Ga-1:(HFD + 100 mg/kg), Ga-2:(HFD + 200 mg/kg), Ga-3:(HFD + 400 mg/kg)].
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Table A2. Metabolite profiling of MeGa using LCMS – QTOF in positive ESI mode.

2

Compound name

Retention Molecular Molecular
Compound structure
time
Formula weight

Tartaric acid

0.842

C4H6O6

150.0278

Ascorbic acid

2.343

C6H8O6

176.0325

Hydroxycitric acid

14.608

C6H8O8

208.1095

2-(butoxycarbonylmethyl)-3butoxycarbonyl-2-hydroxy-3- 22.87
propanolide

C14H23O7

303.2912

Malic acid

C4H6O5

134.1091

23.55
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Table A3. Subacute toxicity effects of MeGa extract for 28 days. (a) Body weight, (b) food intake, (c) haematological analysis, (d)
biochemical analysis (liver and kidney function test) and (e) relative organ weight in male and female rats for normal control, test
(treated with 1000 mg/kg MeGa) and satellite group (treated with 1000 mg/kg MeGa). Values are in mean ± SEM.
Parameters (Unit)

Normal control
Male

Test
Female

Satellite

Male

Female

Male

Female

(a) Body weight (g)

420.90 ± 13.66 256.70 ± 4.34

370.50 ± 8.27

247.10 ± 7.16 422.11 ± 8.20 248.00 ± 4.65

(b) Food intake (g)

85.36 ± 4.50

61.35 ± 0.18

77.10 ± 2.53

58.43 ± 2.26

84.93 ± 2.31

57.66 ± 2.74

White blood cell count (109 /L)

6.53 ± 0.80

6.69 ± 1.24

8.79 ± 1.86

6.53 ± 2.33

9.53 ± 1.97

9.33 ± 1.79

Neutrophils (10 /L)

0.20 ± 0.39

0.33 ± 0.15

0.16 ± 0.01

0.48 ± 0.14

0.28 ± 0.04

0.34 ± 0.14

Lymphocytes (10 /L)

3.12 ± 0.71

3.64 ± 1.06

4.40 ± 1.49

5.93 ± 1.21

5.02 ± 1.49

6.28 ± 1.44

Monocytes (109 /L)

1.20 ± 0.30

1.58 ± 0.29

1.60 ± 0.09

2.07 ± 0.43

2.27 ± 0.28

1.54 ± 0.22

(c) Haematological analysis
9

9

Eosinophils (10 /L)

0.09 ± 0.01

0.16 ± 0.02

0.11 ± 0.02

0.12 ± 0.02

0.17 ± 0.03

0.13 ± 0.04

Red blood cell count (1012 /L)

8.33 ± 0.09

8.36 ± 0.15

8.77 ± 0.27

8.15 ± 0.11

8.34 ± 0.11

8.43 ± 0.08

Hemoglobin (g/dL)

15.03 ± 0.18

16 ± 0.29

16.38 ± 0.55

15.2 ± 0.38

15.95 ± 0.20

15.83 ± 0.44

Hematocrit (%)

46.58 ± 1.52

47.17 ± 1.21

50.17 ± 1.05

47.2 ± 0.61

47.40 ± 0.33

45.43 ± 0.72

Mean red blood cell volume (MCV)
(fL)

55.95 ± 1.57

56.58 ± 0.89

58.23 ± 0.52

55.63 ± 0.64

55.50 ± 1.24

54.10 ± 0.50

Mean corpuscular Hb (pg)

18.08 ± 0.24

18.90 ± 0.06

18.66 ± 0.18

18.88 ± 0.33

19.11 ± 0.28

18.50 ± 0.40

Mean corpuscular Hb concentration
32.30 ±0.76
(MCHC) (g/dL)

32.63 ± 0.47

32.42 ± 0.31

32.93 ± 0.34

33.80 ± 0.32

34.65 ± 0.65

9

(d) Biochemical analysis
ALP (U/L)

135.8 ± 5.05

72.18 ± 6.24

127.52 ± 7.95

88.27 ± 6.24

121.70 ± 5.00 66.87 ± 4.26

ALT (U/L)

45.52 ± 2.12

45.75 ± 3.02

47.53 ± 2.76

43.62 ± 3.82

43.58 ± 1.96

AST (U/L)

125.07 ± 7.77

143.58 ± 11.85 161.48 ± 10.58 148.97 ± 6.53 122.07 ± 5.09 152.40 ± 14.9

CRE (µmol/L)

29.67 ± 2.20

39.50 ± 1.43

34.33 ± 2.51

41.33 ± 3.11

30.67 ± 1.69

36.50 ± 2.77

Liver (%)

2.76 ± 0.05

3.02 ± 0.08

2.88 ± 0.06

3.16 ± 0.06

2.84 ± 0.12

2.92 ± 0.09

Heart (%)

0.35 ± 0.02

0.39 ± 0.01

0.39 ± 0.02

0.40 ± 0.01

0.34 ± 0.02

0.36 ± 0.02

Lung (%)

0.56 ± 0.05

0.67 ± 0.02

0.53 ± 0.01

0.76 ± 0.03

0.47 ± 0.01

0.68 ± 0.03

Kidney (%)

0.70 ± 0.01

0.72 ± 0.02

0.75 ± 0.03

0.75 ± 0.01

0.67 ± 0.02

0.74 ± 0.02

Spleen (%)

0.16 ± 0.01

0.19 ± 0.01

0.17 ± 0.01

0.21 ± 0.01

0.19 ± 0.01

0.18 ± 0.01

Brain (%)

0.51 ± 0.01

0.74 ± 0.02

0.54 ± 0.01

0.78 ± 0.03

0.49 ± 0.01

0.77 ± 0.01

42.32 ± 2.02

(e) Relative organ weight
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Table A4. List of significantly differentiated metabolites and metabolism pathways in different treatment groups. (a) Lean versus obese,
(b) lean versus Adipex and (c) lean versus MeGa (200 mg/kg). Abbreviation: n.d = not detected, dw = down.

Pathway

Metabolism

Biosynthesis of
unsaturated fatty acids

Sphingolipid
metabolism

Lipid
metabolism

Steroid hormone
biosynthesis

Steroid biosynthesis

Primary bile acid
biosynthesis
Glycerophospholipid
metabolism
Metabolism of
cofactors and
vitamins
Signalling
molecules and
interaction

Retinol metabolism
Neuroactive ligandreceptor interaction
Tryptophan
metabolism

Amino acid
metabolism

Tyrosine metabolism
Cysteine and
methionine
metabolism

4

Metabolites

Mass

(a) Lean
versus
obese
pre post

7Z, 10Z, 13Z, 16Z, 19Z-docosapentaenoic acid
4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,1
6,19-Docosahexaenoic acid
5,8,11,14,17-Icosapentaenoic acid

330.2568

n.d up

n.d up

n.d up

256.2392

n.d dw

n.d up

n.d up

302.2237

dw dw

dw up

dw up

Linoleic acid

280.2398

n.d up

n.d dw

n.d dw

Arachidonic Acid (peroxide free)

248.0539

n.d dw

n.d up

n.d up

α-Linolenic Acid

278.2241

up

up

up

Sphinganine
Sphingosine-1-phosphate

301.2977
379.2496

n.d up
n.d up

n.d up
n.d dw

n.d up
n.d dw

Sphinganine-phosphate

381.2635

n.d up

n.d dw

n.d dw

3-ketosphinganine

299.2849

dw up

dw up

dw up

21-Hydroxypregnenolone

348.2299

n.d dw

n.d up

n.d up

progesterone

314.2246

n.d dw

n.d dw

n.d dw

17a-Hydroxyprogesterone

330.2191

n.d dw

n.d up

n.d up

17alpha,21-Dihydroxypregnenolone

348.2289

n.d up

n.d up

n.d up

(20S)-17,20-dihydroxypregn-4-en-3-one

232.1459

n.d up

n.d up

n.d up

Corticosterone

346.2148

n.d dw

n.d up

n.d up

11-Dehydrocorticosterone

344.1987

n.d up

n.d up

n.d up

Calcidiol

400.3359

n.d dw

n.d up

n.d up

Calcitriol

410.3525

n.d up

n.d up

n.d up

Campesterol

400.3722

n.d up

n.d up

n.d up

4,4-Dimethylcholesta-8,14,24-trienol

416.328

n.d up

n.d up

n.d up

3alpha,7alpha,26-Trihydroxy-5beta-cholestane

420.3606

n.d dw

n.d up

n.d up

Cholest-5-ene-3beta,26-diol

402.3506

n.d dw

n.d dw

n.d dw

3α,7α-Dihydroxy-5β-cholestanate

434.34

n.d dw

n.d up

n.d up

Phosphatidylethanolamine

773.5383

n.d up

n.d up

n.d up

Phosphatidylcholine

805.5603

dw up

dw up

dw up

9-cis-retinal

284.2134

up

up

up

up

up

up

9-cis-Retinoic acid

300.208

up

up

up

dw

up

dw

11-cis-Retinol

286.2287

n.d up

n.d dw

n.d dw

Anandamide

328.2611

n.d dw

n.d dw

n.d dw

Arachidonoyl dopamine

439.3095

n.d up

n.d dw

n.d dw

N-Acetylserotonin

218.1049

n.d up

n.d up

n.d up

4,6-Dihydroxyquinoline

161.0463

n.d dw

n.d up

n.d up

L-Kynurenine

208.0836

n.d up

n.d up

n.d up

L-Normetanephrine

183.0902

n.d up

n.d dw

n.d dw

4-Hydroxyphenylacetaldehyde

136.0527

n.d up

n.d up

n.d up

4-Fumarylacetoacetate

200.0339

n.d up

n.d up

n.d up

S-Methyl-5-thio-D-ribose 1-phosphate

260.0095

n.d dw

n.d up

n.d up

up

(b) Lean
versus
Adipex
pre post

(c) Lean
versus
MeGa
pre post

up

up
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Effect of high-fat diet on body weight
500.0
450.0

Body weight (g)

400.0
350.0
300.0
250.0
200.0
150.0
100.0
50.0
0.0

Lean

Obese

Adipex
Ga-1
Groups

Ga-2

Ga-3

Figure A1. Effect of high-fat diet on body weight of the pretreatment lean group and moderately obese groups, including obese, Ga-1
(100 mg/kg MeGa), Ga-2 (200 mg/kg MeGa) and Ga-3 (400 mg/kg MeGa) groups.
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(a)

(b)

(c)

(d)

Lean rat

Obese rat

Adipex-treated rat

Ga-2-treated rat

Figure A2. LC/MS Q-TOF chromatography of serum samples. (a) Lean rat, (b) obese rat, (c) Adipex-treated rat, and (d) MeGa-treated
rat.
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